Plant Name: Physalis longifolia
Taxonomic Information:
Plant ID: NPO14874
Plant Latin Name: Physalis longifolia
Taxonomy Genus: Physalis
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
161495
Plant-of-the-World-Online:
817466-1
Used in Medicines:
Unknown.
Geographical Distribution:
United States; Mexico
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; | |
| NMUR2; | |
| GAA; ACHE; | |
| MAPK1; | |
| POLB; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 6.752E-07 | 4.575E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 6.752E-07 | 4.575E-03 | ADRA2A, ADRA2C |
| BP | GO:0032501; multicellular organismal process | GO:0006940; regulation of smooth muscle contraction | 1.261E-06 | 4.575E-03 | ADRA2A, ADRA2C, NMUR2 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.377E-07 | 4.575E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.149E-06 | 7.618E-03 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.149E-06 | 7.618E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 6.186E-06 | 1.225E-02 | ADRA2A, ADRA2C, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0004574; oligo-1,6-glucosidase activity | 7.247E-04 | 1.962E-01 | GAA |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 7.872E-04 | 2.065E-01 | ACHE, ADRA2A, ADRA2C, GAA, MAPK1, NMUR2 |
| CC | GO:0044464; cell part | GO:0030424; axon | 3.543E-03 | 4.691E-01 | ADRA2C, MAPK1 |
| CC | Unclassified; | GO:0031143; pseudopodium | 6.145E-03 | 6.055E-01 | MAPK1 |
| CC | GO:0044464; cell part | GO:0032839; dendrite cytoplasm | 9.026E-03 | 7.473E-01 | MAPK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.953E-05 | 1.836E-03 | MAPK1, ADRA2C, ADRA2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 8.828E-05 | 4.149E-03 | NMUR2, ADRA2C, ADRA2A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 6.295E-04 | 1.972E-02 | ACHE, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.122E-03 | 4.988E-02 | POLB, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.011E-02 | 6.113E-02 | MAPK1 |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 9.413E-03 | 6.113E-02 | MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.944E-02 | 6.113E-02 | MAPK1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.357E-02 | 6.113E-02 | MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.806E-02 | 6.113E-02 | MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.426E-02 | 6.113E-02 | MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
